To schedule an interview with our team of experts, reach out to:
Jody Schneider
Millennium Health
(619) 917-6810
Jody.Schneider@millenniumhealth.com
Angela G. Huskey, PharmD, CPE
Senior Vice President & Chief Clinical Officer
Dr. Angela G. Huskey leads all clinical aspects of drug testing for substance use treatment, pain management, behavioral health, and primary care. Additionally, she has spearheaded the use of aggregated and de-identified urine drug test (UDT) results to monitor the shifting landscape of drug use nationally. The use of this rich data source allows clinicians, first responders, and those responsible for public health to be quickly informed about these changes to help prevent overdoses and save lives.
Dr. Huskey led her Millennium Health colleagues and a team of experts in the development of a real-time surveillance system called the Emerging Threat Intelligence (ETI) Program™ to provide meaningful, real-time insights into dangerous and evolving trends in drug use nationwide and use these findings to aid the development of rapid health responses. Since the creation of the ETI Program, Millennium Health has entered collaborations with the CDC, U.S. Department of Health and Human Services and the Ohio Department of Public Safety as well as multiple academic partners.
Formerly a pain and palliative care clinician, Dr. Huskey is a nationally recognized expert on drug testing and its role in clinical care. Her passion for its use in the care of individuals and in public health applications is driven by her clinical background and personal experience of caring for a loved one with a substance use disorder (SUD).
Eric Dawson, PharmD
Vice President of Clinical Affairs
Dr. Eric Dawson brings a diverse background of over 25 years of clinical experience, research, and education. He has a particular interest in the issues related to our nation’s substance use crisis, and alongside his team, issues the annual Millennium Health Signals Report™, which serves to educate clinicians, public policy makers and the public regarding trends in illicit drug use. He serves as a point of contact for many of Millennium Health’s collaborations, including the U.S. Department of Health & Human Services, the CDC, Columbia University, Johns Hopkins University, and the Ohio Department of Public Safety. Working with his collaborators, Dr. Dawson has coauthored numerous publications appearing in journals such as JAMA, JAMA Network Open, JAMA Psychiatry, Drug and Alcohol Dependence, and the Journal of Addiction Medicine. He is passionate about educating clinicians and is frequently called upon to give lectures to pharmacists, nurses, and physicians across the country. Dr. Dawson is also a recognized expert regarding our nation’s drug overdose crisis and has been interviewed by national media outlets such as Axios, Medscape and Bloomberg News. Dr. Dawson earned his Doctor of Pharmacy degree from Auburn University graduating with highest honors. He is also a licensed pharmacist in the state of Alabama.
Steven Passik, PhD
Vice President of Scientific Affairs & Head of Clinical Data Programs
After a 25-year career as an academic clinical psychologist working with cancer and non-cancer pain patients and their families, Dr. Steve Passik has now been in industry for nearly 11 years. Having worked at the interface of pain and addiction both clinically and conducting research at Memorial Sloan Kettering Cancer Center, University of Kentucky and Vanderbilt University, Dr. Passik came to industry to contribute to safer pain management and improved addiction recognition and treatment.
He initially began working at Millennium Health with an eye toward strengthening the evidence base underpinning urine drug testing in pain and addiction management. He then spent several years in pharma working to help in the development of safer opioid formulations.
He returns now to Millennium Health as VP, Scientific Affairs and Head of Clinical Data Programs. Dr. Passik has been working alongside colleagues in the Collaborative Data Program on expanding work begun at Millennium Health using aggregated urine drug testing results from around the country to inform clinicians, policy makers and public health officials on the changing landscape of substance use and to help facilitate a data driven approach to this enormous public health problem.
Penn Whitley
Sr. Director, Bioinformatics
Penn Whitley is the Senior Director of Bioinformatics at Millennium Health. Whitley’s research focuses on the relationship between Millennium Health’s urine drug test results and related public health indicators, like fatal and non-fatal overdose, demographic features of the clinical population and poly-substance use trends in the community. Whitley has an extensive background in experimental design, biostatistics, supervised and non-supervised machine learning techniques and epidemiological analysis methods. He also has a strong background in genomics analysis methods like gene/protein expression analysis, germline/somatic mutation detection and other next-generation sequencing based assays.
Whitley has been instrumental in the development of Millennium Health’s Emerging Threat Intelligence Program™, which provides timely drug use information and trends that assist national, regional, and state officials including the Centers for Disease Control and the United States Department of Health and Human Services to assist in their efforts to make a positive impact on our nation’s illicit drug overdose epidemic. Through his efforts, Millennium Health is able to monitor real-time trends in drug use by analyzing over 15 million test results from over 4 million patients representing all 50 states across multiple specialties.
Whitley’s work has been published in numerous journals including JAMA, JAMA Network Open and Addiction and he is a co-author of the annual Millennium Health Signals Report™. He is frequently interviewed by national media outlets.
Kelly Olson, PhD
Director, Clinical Affairs
Dr. Kelly Olson is a neuroscientist, an author, and a keynote speaker who believes in assessing and addressing disease using an integrative approach. She is also an experienced researcher in molecular neuropharmacology and clinical biology in the areas of mental illness, sleep, adrenal fatigue, and addictions. For the past decade, Dr. Olson has sought to improve clinical outcomes for patients by working closely with some of the very best clinicians and other health care providers in the country, studying individual symptomology and responses to medications.
Dr. Olson has authored/co-authored a number of peer-reviewed articles, book chapters, and presentations, and has lectured extensively internationally, nationally, and locally. She received her Master of Science in Exercise Physiology from the University of North Dakota, and her PhD in Pharmacology & Therapeutics from the University of Manitoba.
Levi Bolin, PhD
Associate Director of Clinical Affairs
Dr. Levi Bolin is an Experimental Psychologist and Behavioral Pharmacologist who is interested in the etiology, treatment, and public-health impacts of substance use disorders. For over a decade, Dr. Bolin studied the behavioral effects of drugs and their impact on basic learning, motivation, and decision-making processes involved in the pathology of addiction. His research has been published in numerous peer-reviewed journals including Drug and Alcohol Dependence and the Journal of Addiction Medicine.
As the Associate Director of Clinical Affairs at Millennium Health, Dr. Bolin aims to help improve patient care by providing clinical and scientific support to practicing clinicians and help address the nation’s substance use and overdose crisis by sharing insights into real-time illicit drug and polysubstance use trends from Millennium Health’s Emerging Threat Intelligence (ETI) Program™. He actively contributes to ongoing research within the ETI Program, is a co-author of the Millennium Health Signals Report™, and works closely with several of Millennium Health’s collaborators including the Ohio Department of Public Safety.
Before joining Millennium Health, Dr. Bolin worked in Kentucky’s Department for Behavioral Health, Developmental, and Intellectual Disabilities where he served as a treatment implementation specialist for the Kentucky Opioid Response Effort (KORE) and project director for a SAMHSA-funded initiative to promote integrated primary and behavioral health care. Dr. Bolin received his PhD in Experimental Psychology from the University of Kentucky.